Whooping cough (pertussis) results with PCR-level accuracy are now available at the point of care, enabling primary care clinicians & emergency departments to act quickly, treat appropriately, prevent complications, and control further spread. https://t.co/9XpS4N4WXT $RHHBY $ROG

We’re proud to stand with the global scientific community at #CTAD2025 to advance what’s possible in #Alzheimer’s care. For over 20 years, Roche has worked to change the trajectory of the disease - from early detection to ongoing care. 👉 Learn how we’re charting a new course

Our #ChangingDiabetesInChildren initiative, in collaboration with @novonordisk, has spent 15 years empowering T1D care in resource-limited countries through education & access. Now, we're leveraging evidence-based insights to embed sustainable care into national health plans.

#MEDIA – We’re pleased to announce that the EC has approved our bispecific cancer immunotherapy for subcutaneous use in relapsed or refractory #lymphoma, providing an additional treatment option to suit diverse patient and physician needs. 👉 https://t.co/Qz1zWs1NPr

#MEDIA — We’re pleased to share phase III results from the first oral #SERD to show significant invasive-disease free survival benefit in ER-positive early-stage #BreastCancer. 👉 https://t.co/U2UYBzxH3A $ROG $RHHBY

At Roche, we are committed to pushing the boundaries of healthcare and making life-changing breakthroughs. Mass spectrometry is meeting the needs of the lab of the future for better patient care. Small chemistry enables big impact. https://t.co/CUaZEIz17V #RocheMassSpec

#MEDIA - We’re pleased to share positive Phase III results for our investigational oral, brain-penetrant medicine in primary progressive and relapsing forms of multiple sclerosis. https://t.co/xFTCoZwDZr $RHHBY $ROG

#Diabetes doesn’t just impact the body; its unpredictability can also affect emotions, decision-making, and daily life. But what if people could know what was coming? By harnessing predictive tools, Roche is making that vision a reality. Through the power of forecasting, we aim

#MEDIA - Roche to showcase over 40 abstracts at #ASH25, demonstrating the potential of our innovative portfolio to continue advancing treatment standards in #haemophiliaA and #lymphoma 👉 https://t.co/P9Sbi1uEmr $RHHBY $ROG

#MEDIA – We are excited to share positive results from our phase III trial in systemic lupus erythematosus, a potentially life-threatening autoimmune disease that affects more than three million people worldwide. 👉 https://t.co/xFTCoZwDZr $ROG $RHHBY

New test delivers results in half the time or less compared to current comparable solutions, enabling faster patient management that can lower the risk of severe illness. https://t.co/9XpS4N4WXT $RHHBY $ROG

New GUINNESS WORLD RECORDS™ title received! Our team, in collaboration with Broad Clinical Labs and Boston Children’s Hospital, achieved the fastest DNA sequencing technique: less than 4 hours to sequence a human whole genome! https://t.co/OEal280Tt8 #NGS #Genomics #Innovation

#MEDIA – We are excited to share positive results from our phase III trial in children and young adults with idiopathic nephrotic syndrome, the first global phase III study of a targeted therapy in this chronic disease. https://t.co/NsNy6ZNdKj $ROG $RHHBY

🚀 #ProudMoment! Roche and @Genentech have been recognized among the world’s top #BioPharma employers in @ScienceMagazine 2025 list! Congratulations to all our teams 👏💙 Read more about it here 👉🔗 https://t.co/Lwvw7tQ1rC #SCTopEmployers #InnovationInHealthcare #science

[#MEDIA] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised. For more details on our performance, click here ➡️ https://t.co/QhYwA246CJ

#MEDIA - We are pleased our phase III data at #ESMO25 show personalised, ctDNA-guided treatment can deliver significant survival benefits for people with muscle-invasive #bladdercancer https://t.co/PXJoAzdLRw $ROG $RHHBY

#MEDIA - We are pleased the FDA has approved our medicine for adults with active #lupusnephritis, a potentially life-threatening disease that can lead to irreversible kidney damage. 👉 https://t.co/v2t2HLBjP2

#MEDIA - At #ESMO25, we’ll be presenting results from the first positive head-to-head phase III trial of an all-oral #SERD-containing regimen vs. a standard of care combination in ER-positive advanced #BreastCancer https://t.co/9LmtqDGCsF $ROG $RHHBY

#MEDIA | This year at #AAO2025, we’re pleased to share new phase III data for the first non-steroid targeted therapy designed to address inflammation driving #UME, a serious cause of vision loss. Learn more 👉 https://t.co/pVoZv4eO5Y

#MEDIA - We are pleased the CHMP has recommended approval of our investigational medicine for adults with #lupusnephritis, potentially helping to address the high unmet need for new treatment options if approved. 👉 https://t.co/JsNVNvX8s9 $ROG $RHHBY